| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/01/2004 | WO2002070676A9 Use of protein histidine phosphatase |
| 04/01/2004 | WO2002069900A3 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 04/01/2004 | WO2002060485A9 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 04/01/2004 | WO2002057299A9 Vegfr-3 binding peptides and their use for inhibiting angiogenesis |
| 04/01/2004 | WO1990001943A8 Treatment of myeloid leukemias by inducing terminal differentiation with interleukin-6 |
| 04/01/2004 | US20040063971 Reacting a pyrrolidin-2,5-dione compound with acetylene compound; anticancer agent |
| 04/01/2004 | US20040063955 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines |
| 04/01/2004 | US20040063949 Controlling gene expression of tranforming growth factor |
| 04/01/2004 | US20040063947 Cyclization; antitumor agents |
| 04/01/2004 | US20040063946 Jnk inhibitor |
| 04/01/2004 | US20040063944 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 04/01/2004 | US20040063943 Phosphodiesterase inhibitor; cardiovascular disorders; sexual disorders |
| 04/01/2004 | US20040063907 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/01/2004 | US20040063906 Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides |
| 04/01/2004 | US20040063781 Compounds active at the glucocorticoid receptor II |
| 04/01/2004 | US20040063777 Reacting a maleimide compound with an alkyne derivative containing a leaving group, in presence of a base to form end product useful for treating ras-associated diseases in a mammal |
| 04/01/2004 | US20040063773 Adminstering a pyrrole substituted 2-indolinone compound to a human for the treatment of protein kinase related cellular disorders such as cancer, autoimmune disorders, diabetes, rheumatoid arthritis, angiogenesis and osteoarthritis |
| 04/01/2004 | US20040063759 Administering to a mammal, for treatment or prevention of conditions that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, a piperidinone compound |
| 04/01/2004 | US20040063745 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors |
| 04/01/2004 | US20040063739 Such as 6,8,13-trimethyl-8H-quino(4,3,2-kl)aridinium methyl sulphate for inhibiting telomerase, regulating cell proliferation, and treating proliferative conditions/cancer |
| 04/01/2004 | US20040063733 Quinazoline derivatives |
| 04/01/2004 | US20040063731 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/01/2004 | US20040063730 Such as 5-(7-(3-chloro-4-methoxybenzylamino-1-methyl-3-propyl-1 H-pyrazolo(4,3-d)pyrimidin-5-yl)pentanoic acid; phosphodiesterase inhibitors; for treatment of cardiovascular disorders, asthma, and allergies; kits |
| 04/01/2004 | US20040063727 Rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, cancer, restenosis; synthesis |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063715 Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063705 Substituted pyrimidinyl derivatives and methods of use |
| 04/01/2004 | US20040063700 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 04/01/2004 | US20040063691 Preparation and use of imidazole derivatives for treatment of obesity |
| 04/01/2004 | US20040063688 CCR1 receptor antagonists; such as 5-chloro-2-(2-(-3-(4-fluoro-phenoxy)-8-aza-bicyclo(3.2.1)oct-8-yl)-2-oxo -ethoxy)-benzamide |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063681 Methods for using gold (III) complexes as anti-tumor and anti-HIV agents |
| 04/01/2004 | US20040063677 Omega monounsaturated fatty acid derivativatized biologically active materials; drug delivery; drug resistance; bioavail-ability |
| 04/01/2004 | US20040063675 Synthesis of pancrastistatin |
| 04/01/2004 | US20040063674 Tetracycline compounds having target therapeutic activities |
| 04/01/2004 | US20040063671 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/01/2004 | US20040063665 Anticancer agents; high degree of discrimination toward malignant cells; reducing side effects; nontoxic; such as 3-chloro-2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chromen-4-one |
| 04/01/2004 | US20040063662 Selective cytotoxicity for slow growing abnormal cells |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063649 Azithromycin combination for emesis control in mammals |
| 04/01/2004 | US20040063647 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 04/01/2004 | US20040063644 Urea and urethane derivatives as integrin inhibitors |
| 04/01/2004 | US20040063643 Bombesin antagonists |
| 04/01/2004 | US20040063632 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 04/01/2004 | US20040063623 Formulation of boronic acid compounds |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063142 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof |
| 04/01/2004 | US20040063140 Methods for diagnosis of cancer using erbB-3 |
| 04/01/2004 | US20040063135 Comprises oligonucleotides for determining concentration of glucuonidase in cell culture; detection and monitoring of malignancies and metastasis; targeted drug delivery |
| 04/01/2004 | US20040063131 Comprises neuroendocrine-specific proteins-like polypeptides (NSPLP) for diagnosis, prevention and treatment of neurodegenerative and cell proliferative diseases |
| 04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
| 04/01/2004 | US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction |
| 04/01/2004 | US20040062761 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
| 04/01/2004 | US20040062758 Immunostimulant; mixture of lactobacillus, propionibacterium, bifidobacterium |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | CA2499964A1 Methods and compositions of novel triazine compounds |
| 04/01/2004 | CA2499672A1 Composition of berry extracts that prevents or inhibits angiogenesis and helicobacter pylori |
| 04/01/2004 | CA2499628A1 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug |
| 04/01/2004 | CA2499332A1 Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | CA2499199A1 Leucine-enriched nutritional compositions |
| 04/01/2004 | CA2498662A1 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | CA2498149A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| 04/01/2004 | CA2497971A1 Triazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | CA2497903A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 04/01/2004 | CA2492319A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments |
| 03/31/2004 | EP1403302A1 Process for producing lactic acid oligomer |
| 03/31/2004 | EP1403284A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION |
| 03/31/2004 | EP1403283A1 Tumor antigen |
| 03/31/2004 | EP1403255A1 Rho KINASE INHIBITORS |
| 03/31/2004 | EP1403252A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 03/31/2004 | EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
| 03/31/2004 | EP1402894A1 Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
| 03/31/2004 | EP1402890A1 Sulfonamide derivatives |
| 03/31/2004 | EP1402888A1 The use of substituted carbocyclic compounds as rotamases inhibitors |
| 03/31/2004 | EP1402786A1 Ximenynic acid |
| 03/31/2004 | EP1402262A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
| 03/31/2004 | EP1402253A2 A process for the isolation of a major harmful oxidant from cigarette smoke |
| 03/31/2004 | EP1402070A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402051A2 Lces as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS |
| 03/31/2004 | EP1402032A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 03/31/2004 | EP1402029A2 Use of inhibitors of expression or activity of p8/com1 for treating tumors |
| 03/31/2004 | EP1402018A1 Unigene unidirectional antisense library |
| 03/31/2004 | EP1402017A1 Random gene unidirectional antisense library |
| 03/31/2004 | EP1402007A1 Bcl-2 dnazymes |
| 03/31/2004 | EP1402000A2 Structural and cytoskeleton-associated proteins |
| 03/31/2004 | EP1401999A2 B7 related protein-2 molecules and uses thereof |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401869A1 Molecules and methods for inhibiting shedding of kim-1 |
| 03/31/2004 | EP1401863A1 Somatostatin-dopamine chimeric analogs |
| 03/31/2004 | EP1401862A2 Peptide compounds for counteracting reactive oxygen species and free radicals |